Evidence map›Paper›PMID 29969978›Full record

ArticleInternational journal of STD & AIDS2018

Molecular screening for Neisseria gonorrhoeae antimicrobial resistance markers in Nigerian men who have sex with men and transgender women.

Justin Hardick, Trevor A Crowell, Kara Lombardi, Akindiran Akintunde, Sunday Odeyemi, Andrew Ivo, George Eluwa, Jean Njab, Stefan D Baral, Rebecca G Nowak and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in International journal of STD & AIDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Justin Hardick1 Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-3926-7784
Trevor A Crowell2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Kara Lombardi2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Akindiran Akintunde2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Sunday Odeyemi2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Andrew Ivo2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
George Eluwa5 Population Council Nigeria, Abuja, Nigeria.
Jean Njab5 Population Council Nigeria, Abuja, Nigeria.
Stefan D Baral6 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Rebecca G Nowak7 Institute of Human Virology, University of Maryland, Baltimore, MD, USA.
Thomas C Quinn1 Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kent Barbian9 Rocky Mountain National Laboratory (RML), Hamilton, MT, USA.
Sarah Anzick9 Rocky Mountain National Laboratory (RML), Hamilton, MT, USA.
Sylvia Adebajo5 Population Council Nigeria, Abuja, Nigeria.
Manhattan E Charurat6 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Julie Ake2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Charlotte A Gaydos1 Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USWalter Reed Army Institute of Research · USMedical Laboratory Science Council of Nigeria · NGHenry M. Jackson Foundation · USUniversity of Maryland, Baltimore · US

Funding

Infectious Diseases Research Technologies Core - RMLZICAI001052 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$133.3M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
TrainingU54EB007958 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI Yukari C Manabe, Susan Anne Tuddenham · 2007 to 2026
$34.6M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
UM-IHV AITRP in NigeriaD43TW001041 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 1998 to 2015
$9.2M
Immunopathogenesis Of Chlamydia trachomatis InfectionZIAAI000358 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2009 to 2022
$7.0M
Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeaeR01AI138978 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF · 2018 to 2021
$5.1M
Building TRUSTR01AI120913 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2015 to 2019
$3.3M
TRUSTR01MH099001 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI CHARURAT, MANHATTAN E · 2012 to 2014
$2.9M
FIC NIH HHS D43 TW001041Intramural NIH HHS ZIA AI000361NIAID NIH HHS R01 AI120913NIAID NIH HHS R01 AI138978NIAID NIH HHS UM1 AI068613NIBIB NIH HHS U54 EB007958NIMH NIH HHS R01 MH099001PEPFAR
6 · The paper itself

Abstract

Antimicrobial-resistant Neisseria gonorrhoeae (NG) is a global public health issue that threatens effectiveness of current treatments of NG. Increased use of nucleic acid amplification tests (NAATs) in lieu of cultures makes obtaining clinical isolates for susceptibility testing difficult and samples collected in commercial transport buffer for NAATs do not preserve viable organism, while molecular methods of assessing antibiotic susceptibility do not require viable organism. We evaluated 243 NG-positive samples in Aptima transport media including urine, oral, and rectal swabs from Nigerian men who have sex with men for markers to penicillinase-producing NG, ciprofloxacin ( GyrA and ParC mutations), and extended spectrum cephalosporins (ESCs, PenA mosaic [allele X], PonA, mtrR, PorB mutations) by real-time PCR. NG DNA was recovered in 75% (183/243) of samples. Of these, 93% (171/183) were positive for at least one resistance marker. We observed a prevalence of dual resistance markers to penicillin and ciprofloxacin at 46.2% (79/171). Six percent of samples (10/171) tested positive for the PenA mosaic (allele X) ESC marker. These data indicate that antibiotic-resistant NG is common in Nigeria. Laboratory and clinical capacity building in Nigeria should include development of methods to culture NG and determine antimicrobial susceptibility.

Indexed as

Homosexuality, MaleTransgender PersonsAdultAnti-Bacterial AgentsCeftriaxoneCephalosporinsCiprofloxacinDrug Resistance, Multiple, BacterialFemaleGonorrheaHumansMaleMicrobial Sensitivity TestsNeisseria gonorrhoeaeNigeriaNucleic Acid Amplification TechniquesAnti-Bacterial AgentsCeftriaxoneCephalosporinsCiprofloxacinPenicillinsAfricaantibioticgonorrhea

Identifiers

PMID29969978
PMCPMC6391878
OpenAlexW2810479363

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.